Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A
Figure 4
The CsA/PEG-PLGA-NPs suppress T-cell activation in MLR, CD3-CD28, and ELISpot assays. (a) CsA/PEG-PLGA-NPs showed dose-dependent inhibition of T-cell proliferation in an MLR assay starting at 10 ng/mL equivalent concentration of CsA. (b) CsA/PEG-PLGA-NPs suppressed T-cell proliferation in a CD3-CD28 stimulation assay in a dose-dependent manner starting at 10 ng/mL. PEG-PLGA-NPs was unable to suppress. Data are expressed as the mean cpm of the [H] thymidine uptake by triplicate cultures and represented by the axis. The different concentrations used are represented by the axis (*). Data are representative of two separate experiments. (c) The incidence of cells producing IFN-γ was first measured by ELISpot assay from cultured splenocytes of C57Bl/6 animals responding to BALB/c stimulating splenocytes in vitro. As compared to the positive control (untreated stimulated cells), CsA-NPs reduced the frequency of IFN-γ-producing cells in a concentration-dependent manner (*). Data are representative of two separate experiments (*). (d) IC50 calculation using the percentage of cell proliferation in a MLR assay, measured by thymidine uptake in response to increasing dose of free CsA and CsA equivalent of CsA/PEG-PLGA-NPs (*).